News
BPTH
--
0.00%
--
Stonegate Capital Partners Updates Coverage On Bio-path Holdings, Inc. (Nasdaq:BPTH)
DALLAS, TX / ACCESSWIRE / December 21, 2020 / Bio-Path Holdings, Inc.
ACCESSWIRE · 12/21/2020 19:05
We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 12/11/2020 08:48
Dosing underway in Bio-Path's early-stage BP1002 study
Bio-Path Holdings (BPTH) enrolls the first patient in a Phase 1 clinical trial evaluating the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia ((CLL)) patients. A total of
Seekingalpha · 11/19/2020 13:09
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the enrollment and dosing of the first patient in a Phase 1 clinical trial evaluating the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL) patients.
GlobeNewswire · 11/19/2020 12:00
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the enrollment and dosing of ...
GlobeNewswire · 11/19/2020 12:00
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13/2020 12:40
Bio-Path Holdings Late Thursday Reported Q3 EPS $(0.80) Beats $(0.87) Estimate
Bio-Path Holdings (NASDAQ:BPTH) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.87) by 8.05 percent. This is a 2.56 percent decrease over losses of $(0.78) per share from
Benzinga · 11/13/2020 12:04
Bio-Path Holdings Reports Third Quarter 2020 Financial Results
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the...
GlobeNewswire · 11/13/2020 12:00
Bio-Path Holdings Reports Third Quarter 2020 Financial Results
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2020 and provided an update on recent corporate developments.
GlobeNewswire · 11/13/2020 12:00
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 13, 2020 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2020 and to provide a business overview.
GlobeNewswire · 11/06/2020 13:00
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference c...
GlobeNewswire · 11/06/2020 13:00
Intel, Limelight Networks among major Technology premarket losers' pack
KBS Fashion Group (KBSF) -20%.Puhui Wealth Investment Management (PHCF) -19%.Milestone Pharmaceuticals (MIST) -19% after pricing $45M equity offering.Limelight Networks (LLNW) -18% downgraded at Craig-Hallum after profit miss, margin weakness.Neovasc (NVCN) -15%.Sigma Labs (SGLB) -14% after Q3
Seekingalpha · 10/23/2020 12:24
Mid-Afternoon Market Update: Dow Jumps 200 Points; Align Technology Shares Climb After Q3 Results
Toward the end of trading Thursday, the Dow traded up 0.71% to 28,411.36 while the NASDAQ rose 0.29% to 11,518.30. The S&P also rose, gaining 0.61% to 3,456.52.
Benzinga · 10/22/2020 18:35
Mid-Day Market Update: Crude Oil Rises 2%; InVivo Therapeutics Shares Plummet
Midway through trading Thursday, the Dow traded up 0.04% to 28222.99 while the NASDAQ fell 0.22% to 11,459.67. The S&P also rose, gaining 0.01% to 3,436.
Benzinga · 10/22/2020 16:49
ALGN, AHT, NVIV and TMBR among midday movers
Gainers: Ever-Glory International (EVK) +300%.Sequential Brands (SQBG) +106%.TuanChe (TC) +58%.Hexindai (HX) +34%.Align Technology (ALGN) +33%.KBS Fashion (KBSF) +27%.Ashford Hospitality Trust (AHT) +24%.Bio-Path (BPTH) +21%.First Internet Bancorp (INBK) +20%.LMP Automotive (LMPX) +18%.Losers: InVivo Therapeutics  (NVIV) -45%.Insignia
Seekingalpha · 10/22/2020 16:38
Align Technology, Bio-Path Holdings leads healthcare gainers; InVivo Therapeutics, Teligent among major losers
Gainers: Align Technology (ALGN) +33%, Bio-Path Holdings (BPTH) +23%, Brainstorm Cell Therapeutics (BCLI) +13%, Beam Therapeutics (BEAM) +13%, Cardiff Oncology (CRDF) +10%.Losers: InVivo Therapeutics (NVIV) -45%, Teligent (TLGT) -27%, Aptinyx (APTX) -21%, Iterum Therapeutics (ITRM) -20%, Timber Pharmaceuticals (TMBR) -18%.
Seekingalpha · 10/22/2020 15:04
Thinking about buying stock in Apache Corp, Ford, Norwegian Cruise Line, Bio-Path Holdings, or Adial Pharmaceuticals?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APA, F, NCLH, BPTH, and ADIL.
PR Newswire - PRF · 10/22/2020 14:45
Thinking about buying stock in Apache Corp, Ford, Norwegian Cruise Line, Bio-Path Holdings, or Adial Pharmaceuticals?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APA, F, NCLH, BPTH, and ADIL.
PR Newswire - PRF · 10/22/2020 14:45
ALGN, SDC among premarket gainers
Ever-Glory International (EVK) +115%.Align Technology (ALGN +27% on Q3 results.Bio-Path Holdings (BPTH) +24%. onHelix Energy Solutions Group (HLX +16% on Q3 results.OptiNose (OPTN +14% on preliminary Q3 results.KBS Fashion Group (KBSF) +14%.Marathon Patent Group (MARA) +12%.SmileDirectClub
Seekingalpha · 10/22/2020 12:19
U.S. patent covering prexigebersen lifts Bio-Path
Bio-Path (BPTH) jumps 25% in premarket on moderate volume, after the USPTO issued a Notice of Allowance related to its lead candidate, prexigebersen, in combination with front line cytidine analogues or Bcr-Abl tyrosine
Seekingalpha · 10/22/2020 12:06
Webull provides a variety of real-time BPTH stock news. You can receive the latest news about Bio-Path Holdings through multiple platforms. This information may help you make smarter investment decisions.
About BPTH
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.
More